To the best of our knowledge, the oncogenic implication and therapeutic capacity of SF3B1, its somatic mutations, and expression profile have not been characterized in GBM, neither its association with molecular features nor clinical parameters. This evidence concerns the gene SF3B1 and glioblastoma.